<DOC>
	<DOCNO>NCT00364468</DOCNO>
	<brief_summary>To assess duration severe neutropenia cycle 1 chemotherapy treatment single injection KRN125 multiple daily injection filgrastim .</brief_summary>
	<brief_title>Dose Finding Study KRN125 ( Pegfilgrastim ) Treatment Neutropenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<criteria>patient diagnose malignant lymphoma patient refractory anthracycline anthraquinone contain chemotherapy patient go receive ESHAP CHASE treatment regimen ECOG performance status = &lt; 2 patient appropriate bone marrow , hepatic renal function write informed consent double cancer history bone marrow transplantation PBSCT 2 prior chemotherapy regimen primary hematologic disease myelodysplastic syndrome previous radiotherapy within 4 week enrollment woman childbearing potential either pregnant , breast feeding patient participate clinical trial within last 4 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pegfilgrastim</keyword>
	<keyword>neutropenia</keyword>
	<keyword>cancer patient</keyword>
	<keyword>lymphoma</keyword>
</DOC>